EUCTR2012-004072-19-CZ进行中（未招募）1 期
A randomized, double-blind, parallel group, placebo controlled Phase II study to evaluate the safety and efficacy of inhaled LASAG and Placebo, applied three times daily in adult hospitalized patients with acute serious influenza
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Vectura GmbH
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Age = 18 and = 80 years
- •2)Ability to provide written informed consent prior to performance of any study-related procedure
- •3)Ability to perform controlled inhalations with the AKITA JET device according to the investigator’s opinion
- •4)Indication for hospitalization due to suspected acute severe influenza OR patients with another medical condition (e.g. diabetes mellitus, COPD or other chronic lung disease) worsened by influenza and leading to indication for hospitalization
- •5)Living in a community with documented current influenza transmission, confirmed by viral culture or RT-PCR OR patients with influenza like illness with positive rapid antigen test or RT-PCR at screening
- •NOTE: An influenza outbreak may be documented in the catchment area of the hospital via one of the following methods:
- •1) local confirmation of influenza A or B infection in the current influenza season by
- •a) the institution's local laboratory (by means of RT-PCR or viral culture), or
- •b) the local public health system, or
- •c) the national public health system, or
- •d) a laboratory of a recognized multinational influenza surveillance scheme such as the European Influenza Surveillance Network (EISN) or Pan American Health Organization (PAHO);
- •2) prior enrollment of a PCR positive subject into this study at the same institution in the current influenza season
- •6)Presence of at least one respiratory symptom (nasal congestion, sore throat or cough) of any severity (mild, moderate, or severe) and present admission to hospital due to (suspected) influenza
- •7)Presence of at least one constitutional symptom (aches/myalgia, fatigue headache or feverishness/chills/sweat) of any severity (mild, moderate, or severe) and present admission to hospital due to (suspected) influenza
- •8)Presence of fever at time of screening of = 38.0 °C taken orally, or = 38.5 °C taken rectally or tympanic OR history of documented fever or patient reported symptom of feverishness at any time during 48 hours prior to screening
- •NOTE: Axillary temperature measurement is not allowed for temperature measurement at study site.
- •9)Patient reported onset of illness less than 120 hours (=5 days) before first study drug application
- •NOTE: Time of onset of illness is defined as either (1) the time when the temperature (either oral or rectal or tympanic) was first measured as elevated (at least one degree (°C) of elevation in comparison to first temperature measurement), OR (2) the time when the subject experienced the presence of at least one moderate respiratory symptom AND the presence of at least one moderate constitutional symptom. Axillary temperature measurement is not allowed.
- •NOTE: Please note time point for onset of illness (<72 hours or =72 and <120 hours) in medical records and case report form.
- •10)Female participants of childbearing (reproductive) potential must have a negative urine pregnancy test at screening and agree to use an acceptable method of contraception throughout their participation in the study. Acceptable methods of contraception (a Pearl Index < 1%) include:
- •-hormonal methods (oral contraceptives, patches or medroxyprogesterone acetate)
- •-An intrauterine device (IUD) with a documented failure rate of less than 1% per year
- •-Abstinence may be considered an acceptable method of contraception at the discretion of the investigator
- •NOTE: Females who have been surgically sterilized (e.g., hysterectomy or bilateral tubal ligation) or who are postmenopausal (total
排除标准
- •1)Current clinical evidence or suspicion of an acute non-influenza infectious illness at the time of screening and baseline visit
- •2)Subjects who have been hospitalized due to a condition other than acute influenza and in whom influenza is diagnosed during hospitalization
- •3)Known allergy or hypersensitivity against Acetylsalicylic Acid (ASA) or LASAG
- •4)ASA induced asthma or patients with insufficiently controlled bronchial asthma
- •5)Presence of any chronic lung condition requiring either continuous or intermittent oxygen therapy
- •NOTE: Subjects who are determined to require acute supplemental oxygen therapy at the time of hospital admission may be enrolled, if exclusion criteria regarding mechanical ventilation (see below) are not applicable
- •6)Requirement for acute or chronic mechanical ventilation, either via oral or nasotracheal intubation or via tracheostomy, or chronic or intermittent requirement for BiPAP (bilevel positive airway pressure) at screening
- •NOTE: Subjects who require overnight Continuous Positive Airway Pressure (CPAP) treatment for sleep apnea (without oxygen supplementation) may be enrolled
- •7)Respiratory instability requiring ICU admission resulting in inability to breathe from a nebulizer
- •8)Immunized against influenza with live attenuated virus vaccine in the previous 4 weeks (=4x7 = 28 days)
- •9)Presence of one of the following uncontrolled or unstable cardiovascular diseases: stroke, ECG confirmed acute ischemia or myocardial infarction and/or clinically significant dysrhythmia
- •10)Presence of cardiac signs or symptoms compatible with NYHA Class IV functional status for congestive heart failure
- •11)Known history of gastrointestinal bleeding, uncontrolled peptic or uncontrolled duodenal ulcer
- •12)Known history of moderate or severe renal impairment and/or previous clinical laboratory data indicating an estimated creatinine clearance <30 mL/min during the last 12 months (=12x28 days = 336 days)
- •13)Known history of clinically significant proteinuria ( = 1000 mg/24 hrs) during the last 12 months (=12x28 days = 336 days)
- •14)Presence of currently uncontrolled hyperuricaemia and/or diminished excretion of uric acid without appropriate pharmacotherapy during the last 12 months (=12x28 days = 336 days)
- •15)Known history of unstable cirrhosis or unstable advanced liver disease (Child-Pugh class B or C)
- •16)Known history of hemophilia or other bleeding disorders
- •17)History of organ transplantation, congenital immunodeficiency
- •18)Use of immunosuppressive therapies with a 10mg or more prednisolone-equivalent dose during the last 6 months (=6x28 days = 168 days). Use of inhaled glucocorticoids is permitted
- •19)Known history of human immunodeficiency virus (HIV) infection
- •20)Patients currently on or likely to require anticoagulation with coumarin, heparin, warfarin or similar products
- •NOTE: 1) chronic oral use of ASA (acetylsalicylic acid) at doses of 100mg/day for the purpose of anticoagulation e.g. in patients with coronary artery disease is allowed 2) Heparin (respectively Low Molecular Weight Heparin (LMWH)) for deep venous thrombosis prophylaxis is allowed 3) new generation of anticoagulation therapy (e.g. Pradaxa) is not allowed
- •21)Expected explicit need for NSAIDs (non-steroidal anti-inflammatory drugs) during the study that cannot be covered by symptomatic acetaminophen (i.e. paracetamol) therapy (e.g. patients with chronic rheumatic conditions)
- •NOTE: For the relief of influenza symptom
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind, parallel group, placebo controlled, multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and tamsulosin hydrochloride OCAS 0.4 mg monotherapy, in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component - Neptuneower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).MedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaLower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).EUCTR2008-001211-37-DEAstellas Pharma Europe B.V.1,452
进行中（未招募）
1 期
Study to investigate the safety of a drug called osocimab at low and high doses in adult patients with kidney failure requiring regular hemodialysisPrevention of thromboembolic events in ESRD patients on hemodialysis who are at risk for thromboembolic eventsMedDRA version: 21.1Level: LLTClassification code 10049910Term: Thromboembolism prophylaxisSystem Organ Class: 100000004865MedDRA version: 21.1Level: LLTClassification code 10066622Term: Chronic hemodialysisSystem Organ Class: 100000004865MedDRA version: 21.0Level: PTClassification code 10077512Term: End stage renal diseaseSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2019-003957-27-NLBayer AG750
进行中（未招募）
不适用
A randomized, double-blind, parallel group, placebo controlled, multi center dose ranging study of solifenacin succinate (3 mg, 6 mg and 9 mg) in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy (3 mg, 6 mg and 9 mg) and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms - SATURower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasiaMedDRA version: 8.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaEUCTR2006-002072-18-ATAstellas Pharma Europe B.V.840
招募中
3 期
Study of safety, efficacy and tolerability of ianalumab versus placebo, in combination with Standard of care therapy, in participants with active lupus nephritisCTRI/2023/06/053819ovartis Healthcare Pvt Ltd
进行中（未招募）
1 期
A randomized, double-blind, parallel group, placebo controlled, multi center dose ranging study of solifenacin succinate (3 mg, 6 mg and 9 mg) in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy (3 mg, 6 mg and 9 mg) and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms - SATUREUCTR2006-002072-18-GBAstellas Pharma Europe B.V.840